Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial.

van Vollenhoven RF, Geborek P, Forslind K, Albertsson K, Ernestam S, Petersson IF, Chatzidionysiou K, Bratt J; Swefot study group.

Lancet. 2012 May 5;379(9827):1712-20. doi: 10.1016/S0140-6736(12)60027-0. Epub 2012 Mar 29.

PMID:
22464340
2.

Sick leave and disability pension before and after initiation of antirheumatic therapies in clinical practice.

Neovius M, Simard JF, Klareskog L, Askling J; ARTIS Study Group.

Ann Rheum Dis. 2011 Aug;70(8):1407-14. doi: 10.1136/ard.2010.144139. Epub 2011 Apr 25.

PMID:
21518724
3.

How large are the productivity losses in contemporary patients with RA, and how soon in relation to diagnosis do they develop?

Neovius M, Simard JF, Askling J; ARTIS Study Group.

Ann Rheum Dis. 2011 Jun;70(6):1010-5. doi: 10.1136/ard.2010.136812. Epub 2011 Mar 15.

PMID:
21406455
4.
5.

Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial.

Saevarsdottir S, Wallin H, Seddighzadeh M, Ernestam S, Geborek P, Petersson IF, Bratt J, van Vollenhoven RF; SWEFOT Trial Investigators Group.

Ann Rheum Dis. 2011 Mar;70(3):469-75. doi: 10.1136/ard.2010.139212. Epub 2010 Dec 13.

PMID:
21149498
6.

Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden.

Neovius M, Simard JF, Askling J; ARTIS study group.

Ann Rheum Dis. 2011 Apr;70(4):624-9. doi: 10.1136/ard.2010.133371. Epub 2010 Dec 13.

PMID:
21149495
7.

Ten years with biologics: to whom do data on effectiveness and safety apply?

Simard JF, Arkema EV, Sundström A, Geborek P, Saxne T, Baecklund E, Coster L, Dackhammar C, Jacobsson L, Feltelius N, Lindblad S, Rantapää-Dahlqvist S, Klareskog L, van Vollenhoven RF, Neovius M, Askling J.

Rheumatology (Oxford). 2011 Jan;50(1):204-13. doi: 10.1093/rheumatology/keq326. Epub 2010 Nov 16.

PMID:
21084326
8.

Small-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009.

Neovius M, Sundström A, Simard J, Wettermark B, Cars T, Feltelius N, Askling J, Klareskog L; ARTIS Study Group.

Scand J Rheumatol. 2011 Jan;40(1):8-15. doi: 10.3109/03009742.2010.493895. Epub 2010 Oct 18.

PMID:
20955087
9.

Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?

Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, Dackhammar C, Feltelius N, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Rantapää-Dahlqvist S, Saxne T, Klareskog L.

Arthritis Rheum. 2009 Nov;60(11):3180-9. doi: 10.1002/art.24941.

10.

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial.

van Vollenhoven RF, Ernestam S, Geborek P, Petersson IF, Cöster L, Waltbrand E, Zickert A, Theander J, Thörner A, Hellström H, Teleman A, Dackhammar C, Akre F, Forslind K, Ljung L, Oding R, Chatzidionysiou A, Wörnert M, Bratt J.

Lancet. 2009 Aug 8;374(9688):459-66. doi: 10.1016/S0140-6736(09)60944-2.

PMID:
19665644

Supplemental Content

Loading ...
Support Center